Which has higher earnings & valuation, ARTV or ACRV?

Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artiva Biotherapeutics N/A N/A -$83.86M -$3.54 N/A Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A

Is ARTV or ACRV more profitable?

Acrivon Therapeutics' return on equity of -64.43% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -73.15% -62.74% Acrivon Therapeutics N/A -64.43% -57.08%

Does the media prefer ARTV or ACRV?

In the previous week, Artiva Biotherapeutics had 13 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 17 mentions for Artiva Biotherapeutics and 4 mentions for Acrivon Therapeutics. Artiva Biotherapeutics' average media sentiment score of 1.78 beat Acrivon Therapeutics' score of 0.05 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Acrivon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ACRV or EDIT?

In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 4 articles in the media. Editas Medicine's average media sentiment score of 0.92 beat Acrivon Therapeutics' score of 0.05 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, FULC or ACRV?

Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fulcrum Therapeutics N/A N/A -$74.88M -$1.15 N/A Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A

Is FULC or ACRV more profitable?

Fulcrum Therapeutics' return on equity of -28.54% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Fulcrum Therapeutics N/A -28.54% -27.16% Acrivon Therapeutics N/A -64.43% -57.08%

Does the media prefer FULC or ACRV?

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 8 mentions for Fulcrum Therapeutics and 4 mentions for Acrivon Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.09 beat Acrivon Therapeutics' score of 0.05 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acrivon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ACRV or JMAC?

Acrivon Therapeutics currently has a consensus price target of $11.67, indicating a potential upside of 677.78%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, ACRV or JMAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A Maxpro Capital Acquisition N/A N/A N/A N/A N/A

Is ACRV or JMAC more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% Maxpro Capital Acquisition N/A N/A N/A

Do analysts recommend ACRV or ZSQR?

Acrivon Therapeutics currently has a consensus price target of $11.67, suggesting a potential upside of 677.78%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ACRV or ZSQR?

In the previous week, Acrivon Therapeutics had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 2 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.95 beat Acrivon Therapeutics' score of 0.05 indicating that Coeptis Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Coeptis Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Acrivon Therapeutics (ACRV) Competitors

$1.50 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.52 +0.01 (+1.00%)

As of 07/31/2026 07:34 PM Eastern

Compare

ACRV vs. ARTV, EDIT, FULC, JMAC, and ZSQR

Should you buy Acrivon Therapeutics stock or one of its competitors? MarketBeat compares Acrivon Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acrivon Therapeutics include Artiva Biotherapeutics (ARTV), Editas Medicine (EDIT), Fulcrum Therapeutics (FULC), Maxpro Capital Acquisition (JMAC), and Coeptis Therapeutics (ZSQR).

How does Acrivon Therapeutics compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Artiva Biotherapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

In the previous week, Artiva Biotherapeutics had 13 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 17 mentions for Artiva Biotherapeutics and 4 mentions for Acrivon Therapeutics. Artiva Biotherapeutics' average media sentiment score of 1.78 beat Acrivon Therapeutics' score of 0.05 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Acrivon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Artiva Biotherapeutics currently has a consensus price target of $39.00, indicating a potential upside of 286.14%. Acrivon Therapeutics has a consensus price target of $11.67, indicating a potential upside of 677.78%. Given Acrivon Therapeutics' higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	N/A	N/A	-$83.86M	-$3.54	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

Acrivon Therapeutics' return on equity of -64.43% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Acrivon Therapeutics	N/A	-64.43%	-57.08%

71.6% of Acrivon Therapeutics shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Acrivon Therapeutics beats Artiva Biotherapeutics on 7 of the 13 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Editas Medicine?

Acrivon Therapeutics (NASDAQ:ACRV) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Acrivon Therapeutics has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Editas Medicine	$40.52M	6.23	-$160.06M	-$1.23	N/A

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Acrivon Therapeutics has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Acrivon Therapeutics' return on equity of -64.43% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Editas Medicine	-281.59%	-677.39%	-58.25%

Acrivon Therapeutics has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

Acrivon Therapeutics presently has a consensus target price of $11.67, indicating a potential upside of 677.78%. Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 109.30%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Acrivon Therapeutics is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 4 articles in the media. Editas Medicine's average media sentiment score of 0.92 beat Acrivon Therapeutics' score of 0.05 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Acrivon Therapeutics beats Editas Medicine on 8 of the 14 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Fulcrum Therapeutics presently has a consensus price target of $8.20, suggesting a potential upside of 129.05%. Acrivon Therapeutics has a consensus price target of $11.67, suggesting a potential upside of 677.78%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Fulcrum Therapeutics' return on equity of -28.54% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-28.54%	-27.16%
Acrivon Therapeutics	N/A	-64.43%	-57.08%

Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.15	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 8 mentions for Fulcrum Therapeutics and 4 mentions for Acrivon Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.09 beat Acrivon Therapeutics' score of 0.05 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acrivon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fulcrum Therapeutics has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

Summary

Fulcrum Therapeutics beats Acrivon Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Maxpro Capital Acquisition?

Acrivon Therapeutics (NASDAQ:ACRV) and Maxpro Capital Acquisition (NASDAQ:JMAC) are related small-cap companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Maxpro Capital Acquisition's return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Maxpro Capital Acquisition	N/A	N/A	N/A

Acrivon Therapeutics has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

Acrivon Therapeutics currently has a consensus price target of $11.67, indicating a potential upside of 677.78%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Acrivon Therapeutics had 4 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 0 mentions for Maxpro Capital Acquisition. Acrivon Therapeutics' average media sentiment score of 0.05 beat Maxpro Capital Acquisition's score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Acrivon Therapeutics	Neutral
Maxpro Capital Acquisition	Neutral

Summary

Acrivon Therapeutics beats Maxpro Capital Acquisition on 6 of the 10 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Coeptis Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Coeptis Therapeutics (NASDAQ:ZSQR) are related small-cap companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Acrivon Therapeutics has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Acrivon Therapeutics' return on equity of -64.43% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Acrivon Therapeutics had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 2 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.95 beat Acrivon Therapeutics' score of 0.05 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coeptis Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Acrivon Therapeutics has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.19, indicating that its stock price is 119% less volatile than the broader market.

Coeptis Therapeutics has higher revenue and earnings than Acrivon Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Coeptis Therapeutics	$1.36M	181.90	-$11.92M	-$2.52	N/A

Acrivon Therapeutics currently has a consensus price target of $11.67, suggesting a potential upside of 677.78%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Acrivon Therapeutics beats Coeptis Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Acrivon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRV vs. The Competition

Export

Metric	Acrivon Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$64.20M	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-0.75	7.38	282.30	24.66
Price / Sales	N/A	1,200.34	563.12	75.93
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	0.42	16.96	10.96	6.07
Net Income	-$77.90M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-3.85%	-1.77%	-0.64%	-0.44%
1 Month Performance	-12.79%	-8.39%	-5.23%	-4.81%
1 Year Performance	19.05%	48.40%	61.97%	18.61%

Acrivon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRV Acrivon Therapeutics	3.8106 of 5 stars	$1.50 flat	$11.67 +677.8%	+19.0%	$64.20M	N/A	N/A	58
ARTV Artiva Biotherapeutics	4.1575 of 5 stars	$10.26 -0.6%	$39.00 +280.0%	+256.9%	$254.61M	N/A	N/A	81	Positive News Upcoming Earnings Insider Trade
EDIT Editas Medicine	3.011 of 5 stars	$2.59 -3.5%	$5.40 +108.9%	+5.7%	$253.10M	$40.52M	N/A	230	News Coverage Positive News
FULC Fulcrum Therapeutics	3.4602 of 5 stars	$3.71 -0.7%	$8.20 +121.3%	-47.6%	$247.54M	N/A	N/A	100	Earnings Report Upcoming Earnings
JMAC Maxpro Capital Acquisition	N/A	$18.21 -3.4%	N/A	+193.8%	$244.52M	N/A	N/A	2,021

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRV) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. ARTV, EDIT, FULC, JMAC, and ZSQR

How does Acrivon Therapeutics compare to Artiva Biotherapeutics?

Summary

How does Acrivon Therapeutics compare to Editas Medicine?

Summary

How does Acrivon Therapeutics compare to Fulcrum Therapeutics?

Summary

How does Acrivon Therapeutics compare to Maxpro Capital Acquisition?

Summary

How does Acrivon Therapeutics compare to Coeptis Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. ARTV, EDIT, FULC, JMAC, and ZSQR

How does Acrivon Therapeutics compare to Artiva Biotherapeutics?

Which has more volatility & risk, ARTV or ACRV?

Does the media prefer ARTV or ACRV?

Do analysts recommend ARTV or ACRV?

Which has higher earnings & valuation, ARTV or ACRV?

Is ARTV or ACRV more profitable?

Do institutionals & insiders have more ownership in ARTV or ACRV?

Summary

How does Acrivon Therapeutics compare to Editas Medicine?

Which has better earnings and valuation, ACRV or EDIT?

Do institutionals and insiders believe in ACRV or EDIT?

Is ACRV or EDIT more profitable?

Which has more volatility & risk, ACRV or EDIT?

Do analysts rate ACRV or EDIT?

Does the media favor ACRV or EDIT?

Summary

How does Acrivon Therapeutics compare to Fulcrum Therapeutics?

Do analysts recommend FULC or ACRV?

Is FULC or ACRV more profitable?

Which has better valuation & earnings, FULC or ACRV?

Do institutionals & insiders hold more shares of FULC or ACRV?

Does the media prefer FULC or ACRV?

Which has more volatility & risk, FULC or ACRV?

Summary

How does Acrivon Therapeutics compare to Maxpro Capital Acquisition?

Which has higher valuation & earnings, ACRV or JMAC?

Is ACRV or JMAC more profitable?

Which has more risk and volatility, ACRV or JMAC?

Do analysts prefer ACRV or JMAC?

Do institutionals and insiders believe in ACRV or JMAC?

Does the media favor ACRV or JMAC?

Summary

How does Acrivon Therapeutics compare to Coeptis Therapeutics?

Is ACRV or ZSQR more profitable?

Do institutionals & insiders hold more shares of ACRV or ZSQR?

Does the media favor ACRV or ZSQR?

Which has more risk and volatility, ACRV or ZSQR?

Which has higher earnings & valuation, ACRV or ZSQR?

Do analysts recommend ACRV or ZSQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools